Faruqi & Faruqi, LLP Launches Investigation of Rezolute, Inc. Following Stock Collapse

Investigation of Rezolute, Inc. by Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation concerning potential claims on behalf of investors in Rezolute, Inc. (ticker symbol: RZLT). This inquiry comes in light of significant losses experienced by shareholders following a dramatic plunge in the company's stock price.

On December 11, 2025, Rezolute’s share price fell sharply, igniting concerns across the investment community. The decline was primarily triggered by disappointing outcomes from the Phase 3 clinical trial of its leading drug candidate, ersodetug, intended for treating congenital hyperinsulinism. The clinical trial failed to meet its key primary and secondary endpoints, raising eyebrows among investors. Reports indicated that the maximum dosage of the drug did not yield statistically significant reductions in hypoglycemia events when compared to a placebo, leading to dismay and losses among shareholders.

During the trading session that day, Rezolute’s stock plummeted from closing figures around $10.94 per share to an unprecedented low of approximately $0.90, representing a staggering loss of nearly 85-90%. Such a drastic drop not only highlighted the volatility of the stock but also led to a temporary halting of trading under Nasdaq's volatility controls, signaling the panic among investors.

James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, has publicly encouraged those who suffered substantial financial losses related to Rezolute to reach out for a consultation regarding their legal options. His firm, known for recovering hundreds of millions of dollars for investors since its establishment in 1995, holds offices across key locations including New York, Pennsylvania, California, and Georgia, focusing on representing the interests of aggrieved investors.

Faruqi & Faruqi is dedicated to keeping investors informed about potential claims and legal rights associated with Rezolute. As the investigation unfolds, the firm invites impacted stakeholders to learn more about their options. For more detailed information regarding the ongoing investigation and to see if your claims qualify, interested parties are encouraged to visit the firm’s website or contact them directly via phone.

The investigation may bring light to factors surrounding the company’s operational decisions and financial disclosures leading up to the trial's outcomes. This could provide key insights for understanding how Rezolute’s management may have influenced market performance and investor confidence.

With the stakes high for many investors, it is crucial for those impacted to stay vigilant and informed. Legal avenues may be available for stakeholders to seek redress for their losses. As we await more details from Faruqi & Faruqi’s investigation into Rezolute, investors are advised to monitor developments closely, considering the recent events and their implications on the company's future.

In an industry where investor trust can easily be shaken, this case recalls the importance of thorough due diligence and the necessity of legal support to navigate through turbulent times in the stock market. The investigation by Faruqi & Faruqi may open discussions about accountability and corporate governance within the pharmaceutical sector, ultimately aiming to protect investor interests moving forward.